News brief
According to European Biotechnology, Rivercell raised USD 25 million on 10/7, led by HV Capital. It is building AI virtual cell models to digitalize key validation stages of drug discovery, aiming to shorten new drug development cycles and reduce early trial-and-error costs.
Connected profiles
Explore
Sources · 1Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
- european-biotechnology.com ↗Published Oct 7, 2026
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
据European Biotechnology报道，Rivercell于10月7日完成2500万美元融资，由HV Capital领投。公司正在构建AI虚拟细胞模型，希望将药物发现的关键验证环节数字化，从而缩短新药研发周期、降低前期试错成本。